data_1hze_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1hze _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.0 mtt . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.232 0.539 . . . . 0.0 110.332 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.624 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 5.3 p90 -169.76 139.61 2.0 Allowed 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.211 -0.93 . . . . 0.0 108.898 173.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.534 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 65.4 p -133.92 -38.04 0.89 Allowed 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.145 -0.972 . . . . 0.0 109.404 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 53.16 19.31 7.57 Favored Glycine 0 N--CA 1.482 1.727 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -177.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.534 ' CD1' ' HB ' ' A' ' 3' ' ' THR . 81.2 mt -78.97 128.62 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.098 -1.236 . . . . 0.0 109.734 -176.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t -93.39 136.61 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.056 -1.027 . . . . 0.0 110.816 -171.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -71.82 -30.9 65.99 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.609 -0.682 . . . . 0.0 111.391 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.61 178.96 31.92 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.401 -1.857 . . . . 0.0 110.52 -172.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 24.0 p -127.92 169.99 13.34 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.163 -1.198 . . . . 0.0 110.624 -179.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.547 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -137.39 149.05 46.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.509 -0.745 . . . . 0.0 109.545 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.2 tttt -103.72 115.62 30.82 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 120.937 -1.102 . . . . 0.0 110.121 178.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.506 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.6 tp -59.71 127.27 31.16 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 120.885 -1.134 . . . . 0.0 108.526 171.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.599 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.37 -31.76 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.591 -0.843 . . . . 0.0 110.129 -176.598 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.42 141.8 28.74 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.044 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.586 ' CG1' ' CG2' ' A' ' 78' ' ' VAL . 9.5 mt -109.03 134.88 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.104 -0.998 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.4 m-20 -109.55 115.16 29.4 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.404 -0.81 . . . . 0.0 109.824 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.43 113.88 27.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.109 -0.994 . . . . 0.0 110.635 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.0 mtmt -113.88 126.03 28.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.204 -0.935 . . . . 0.0 108.952 174.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.39 -22.88 12.8 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.751 1.395 . . . . 0.0 110.128 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.577 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 13.1 m-80 -79.91 -41.86 25.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.96 174.853 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.577 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.0 m-85 -156.61 150.32 24.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.454 -0.779 . . . . 0.0 110.022 -178.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.47 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.2 ttt180 -91.26 144.84 25.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.781 -1.199 . . . . 0.0 110.236 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.7 m -129.82 138.1 50.82 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.611 -0.681 . . . . 0.0 109.668 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.546 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.91 140.05 51.85 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.903 -1.123 . . . . 0.0 111.24 178.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.527 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 10.8 t -119.99 134.12 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.061 -1.024 . . . . 0.0 110.542 -176.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.463 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 11.3 m -119.26 170.03 9.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 CA-C-O 121.082 0.468 . . . . 0.0 110.14 -178.028 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.48 ' CB ' ' HB3' ' A' ' 11' ' ' LYS . 11.3 tt0 -103.53 117.68 34.98 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.393 -0.817 . . . . 0.0 108.951 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.465 HD21 ' O ' ' A' ' 32' ' ' MET . 10.2 tp -83.49 130.24 56.96 Favored Pre-proline 0 C--N 1.298 -1.641 0 O-C-N 121.405 -0.809 . . . . 0.0 110.144 -173.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.471 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 29.0 Cg_endo -67.69 175.89 5.7 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 O-C-N 123.935 1.492 . . . . 0.0 111.041 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 54.1 t0 -59.97 -40.02 87.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.292 -0.88 . . . . 0.0 111.161 -174.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.73 56.95 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.77 -1.206 . . . . 0.0 110.803 -174.084 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.53 -15.65 13.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.903 -1.123 . . . . 0.0 109.713 170.394 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.554 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 27.2 mt -68.39 -34.35 75.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.327 -0.858 . . . . 0.0 110.182 175.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 50.7 t0 -89.6 111.75 22.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 110.288 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 120.29 -53.92 0.67 Allowed Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.323 176.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 9.5 tt -60.07 147.97 37.4 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.906 -1.349 . . . . 0.0 110.792 -174.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.468 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 21.9 pt-20 -143.43 166.91 23.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.478 -0.764 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.524 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.69 154.69 41.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 179.577 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.82 0.36 59.45 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -175.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' A' ' 37' ' ' GLU . . . -79.45 160.11 26.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -1.169 . . . . 0.0 109.406 176.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -98.37 112.18 24.27 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.883 -1.136 . . . . 0.0 109.816 177.227 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.58 ' HB ' ' CE2' ' A' ' 61' ' ' PHE . 1.6 t -102.05 127.84 55.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.377 -0.827 . . . . 0.0 109.164 175.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.92 119.84 32.63 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.228 173.13 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.573 ' CE1' HG13 ' A' ' 42' ' ' VAL . 1.2 m80 -90.05 107.66 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.75 -0.78 . . . . 0.0 108.905 177.362 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 53.02 16.07 0.68 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.436 -0.79 . . . . 0.0 110.92 -168.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 116.08 2.96 19.99 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.911 171.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.528 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 24.7 t -99.22 111.53 23.89 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.356 -1.673 . . . . 0.0 109.269 174.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.43 ' SG ' ' O ' ' B' ' 3' ' ' THR . 26.1 p -78.35 125.6 29.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.983 -1.073 . . . . 0.0 111.269 -170.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.528 ' CD2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -135.34 170.52 15.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.245 -0.909 . . . . 0.0 109.363 169.939 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -102.54 151.23 22.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.757 -1.214 . . . . 0.0 110.786 -175.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.551 ' CG1' HG11 ' A' ' 59' ' ' VAL . 17.8 t -77.88 112.57 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.73 -0.606 . . . . 0.0 110.118 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.1 p -69.59 -40.0 76.96 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.25 -0.906 . . . . 0.0 109.822 176.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.512 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -165.44 151.82 9.92 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.816 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.524 HD11 ' CG2' ' A' ' 38' ' ' THR . 8.1 mt -106.45 131.68 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.197 -0.939 . . . . 0.0 110.021 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.465 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.7 m-80 -105.55 65.52 0.72 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.544 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.62 -115.37 4.37 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -172.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.554 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.28 -20.88 43.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.015 -1.285 . . . . 0.0 109.226 175.874 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.599 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 8.2 m170 -75.48 158.94 31.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.176 -0.952 . . . . 0.0 109.998 -177.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 86.0 t -141.65 120.27 9.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 C-N-CA 119.11 -1.036 . . . . 0.0 111.007 174.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.527 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 22.0 m -87.17 128.36 35.13 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.711 -0.618 . . . . 0.0 109.819 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 97.8 m-85 -113.44 159.97 18.94 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.854 -1.154 . . . . 0.0 110.03 177.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.543 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -93.68 147.27 23.18 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.126 -0.984 . . . . 0.0 111.456 -178.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.592 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -154.93 115.22 3.84 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -176.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.514 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 52.2 ttm -70.75 139.42 51.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.254 . . . . 0.0 109.388 178.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 20.0 tttt -60.08 -42.56 94.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.019 -1.05 . . . . 0.0 110.129 -177.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -69.72 -39.96 76.54 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.881 -1.137 . . . . 0.0 109.986 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.514 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -61.14 -35.38 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.891 -1.131 . . . . 0.0 109.242 172.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.592 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 26.7 tp -60.01 -43.24 95.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.107 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 49.9 ttt85 -69.83 -39.98 76.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.263 -0.898 . . . . 0.0 110.678 173.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.467 ' CG2' HG22 ' A' ' 71' ' ' THR . 1.0 OUTLIER -63.03 -41.78 94.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.163 -0.961 . . . . 0.0 109.185 -177.171 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.467 HG22 ' CG2' ' A' ' 70' ' ' ILE . 16.2 p -88.85 -174.47 4.51 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.071 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.474 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 1.8 t30 -102.98 24.31 10.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 171.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.535 ' CD1' HD21 ' A' ' 63' ' ' LEU . 71.7 mt -68.03 -39.96 83.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.051 . . . . 0.0 110.099 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.534 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -45.3 -23.92 0.86 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -65.71 -19.54 65.94 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.049 -1.265 . . . . 0.0 110.686 -176.409 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.3 mt -61.19 143.74 54.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.2 -0.937 . . . . 0.0 110.831 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.488 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 74.6 mttt -147.68 139.57 24.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.644 -0.66 . . . . 0.0 109.761 175.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.586 ' CG2' ' CG1' ' A' ' 15' ' ' ILE . 20.0 t -61.97 154.05 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 120.789 -1.194 . . . . 0.0 110.412 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.69 -14.67 59.42 Favored Glycine 0 N--CA 1.481 1.683 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -174.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 33.2 t0 -99.86 170.0 8.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.416 -1.05 . . . . 0.0 109.54 176.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.9 m95 -117.4 168.24 10.54 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.943 -1.098 . . . . 0.0 110.327 176.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.547 ' CG1' ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -129.88 154.7 40.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.442 -0.786 . . . . 0.0 110.004 -178.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.462 ' N ' HG23 ' A' ' 82' ' ' VAL . 2.2 m-20 -80.47 107.53 13.35 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.107 -0.996 . . . . 0.0 109.164 168.288 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.446 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -107.82 139.19 30.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.412 -1.43 . . . . 0.0 111.163 -175.762 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -136.34 141.47 43.76 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.09 -178.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.464 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 50.1 ptt85 -81.92 131.85 35.26 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.175 -0.953 . . . . 0.0 111.046 -175.425 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.599 ' CB ' ' CZ ' ' B' ' 2' ' ' PHE . . . -126.14 145.81 50.21 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.271 -0.893 . . . . 0.0 110.19 176.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -133.09 143.12 49.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.674 -0.642 . . . . 0.0 110.54 -177.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.6 mmtp -69.95 -40.02 75.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.259 -0.901 . . . . 0.0 110.196 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -148.02 159.99 43.32 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.31 -0.869 . . . . 0.0 110.074 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.471 ' HB3' HG12 ' A' ' 94' ' ' ILE . 37.4 t -149.96 160.61 43.47 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.179 -0.951 . . . . 0.0 110.509 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -66.51 -36.75 83.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 110.569 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -143.25 72.22 1.36 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.032 -1.043 . . . . 0.0 110.463 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.471 HG12 ' HB3' ' A' ' 91' ' ' SER . 25.0 mm -59.99 -45.04 95.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.309 -0.87 . . . . 0.0 109.686 174.658 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 83.31 -45.94 3.55 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.566 ' O ' ' CD2' ' A' ' 97' ' ' HIS . . . 91.22 119.97 2.35 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -177.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.566 ' CD2' ' O ' ' A' ' 96' ' ' GLY . 20.3 m170 . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.271 -1.134 . . . . 10.279999999999999 110.202 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.3 mtt . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 120.968 0.413 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.599 ' CZ ' ' CB ' ' A' ' 87' ' ' ALA . 5.2 p90 -167.23 139.48 3.34 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.955 -1.091 . . . . 0.0 109.06 171.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.52 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 65.0 p -133.97 -38.05 0.89 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.089 -1.007 . . . . 0.0 109.364 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 53.15 19.39 7.66 Favored Glycine 0 N--CA 1.482 1.738 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.021 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.52 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 81.1 mt -79.05 128.59 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 109.745 -176.521 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t -93.33 136.68 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.05 -1.032 . . . . 0.0 110.795 -171.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -71.98 -30.48 65.3 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.641 -0.662 . . . . 0.0 111.448 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.95 178.69 32.36 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 118.515 -1.802 . . . . 0.0 110.603 -172.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 23.9 p -127.9 169.94 13.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.156 -1.202 . . . . 0.0 110.657 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.544 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -137.35 149.18 46.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.563 -0.711 . . . . 0.0 109.497 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.594 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.2 tttt -103.75 115.73 31.02 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.004 -1.06 . . . . 0.0 110.057 178.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.516 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.6 tp -59.93 127.27 31.06 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.964 -1.085 . . . . 0.0 108.579 171.788 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.596 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.24 -32.03 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.143 -176.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.26 141.74 28.88 Favored 'General case' 0 C--N 1.296 -1.725 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.121 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.579 ' CG1' ' CG2' ' B' ' 78' ' ' VAL . 9.7 mt -108.94 134.88 49.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.119 -0.988 . . . . 0.0 110.29 173.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.66 115.31 29.65 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.464 -0.772 . . . . 0.0 109.8 173.139 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.48 113.87 27.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.066 -1.021 . . . . 0.0 110.569 -175.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.0 mtmt -113.9 125.9 28.79 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.9 . . . . 0.0 109.07 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.35 -22.91 12.69 Favored 'Trans proline' 0 C--N 1.304 -1.795 0 O-C-N 123.708 1.373 . . . . 0.0 110.105 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 13.1 m-80 -79.78 -42.26 24.85 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 109.867 174.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.0 m-85 -156.33 150.33 25.17 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 110.001 -178.516 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.468 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.2 ttt180 -91.2 144.74 25.31 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.872 -1.142 . . . . 0.0 110.319 179.2 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.487 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 98.5 m -129.78 138.12 50.88 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.603 -0.686 . . . . 0.0 109.73 -177.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.554 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.8 140.12 51.86 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.941 -1.099 . . . . 0.0 111.156 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.52 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 10.7 t -119.98 134.21 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 110.568 -176.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.478 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 11.3 m -119.43 170.04 9.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.904 -0.498 . . . . 0.0 110.046 -177.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.479 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 11.3 tt0 -103.51 117.75 35.15 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.394 -0.816 . . . . 0.0 108.976 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.484 HD12 ' HD2' ' B' ' 29' ' ' PRO . 10.2 tp -83.45 130.11 57.6 Favored Pre-proline 0 C--N 1.298 -1.646 0 O-C-N 121.234 -0.917 . . . . 0.0 110.195 -173.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.484 ' HD2' HD12 ' B' ' 28' ' ' LEU . 29.0 Cg_endo -67.67 175.91 5.67 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 O-C-N 123.895 1.471 . . . . 0.0 111.041 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' B' ' 30' ' ' ASP . 54.0 t0 -60.01 -40.02 87.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.29 -0.881 . . . . 0.0 111.126 -174.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.571 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.97 0.61 57.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.785 -1.197 . . . . 0.0 110.74 -174.039 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.571 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.44 -15.67 13.86 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.851 -1.156 . . . . 0.0 109.724 170.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 27.1 mt -68.38 -34.35 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.33 -0.856 . . . . 0.0 110.178 175.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -89.64 111.73 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -0.92 . . . . 0.0 110.278 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 120.39 -53.95 0.67 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.782 -1.199 . . . . 0.0 110.363 176.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.5 tt -59.99 148.04 36.84 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.975 -1.309 . . . . 0.0 110.817 -174.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.467 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 21.9 pt-20 -143.46 166.92 23.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.536 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.72 154.68 41.64 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.057 -1.027 . . . . 0.0 110.081 179.567 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.8 0.35 59.3 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -175.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.467 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -79.54 160.02 26.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -1.181 . . . . 0.0 109.408 176.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.48 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -98.15 111.98 24.11 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.821 -1.175 . . . . 0.0 109.957 177.239 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.579 HG12 ' CE1' ' B' ' 44' ' ' HIS . 1.6 t -102.06 127.86 55.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.398 -0.814 . . . . 0.0 109.13 175.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.86 119.78 32.53 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.277 173.08 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.579 ' CE1' HG12 ' B' ' 42' ' ' VAL . 1.2 m80 -89.98 107.63 19.23 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.354 -0.841 . . . . 0.0 109.009 177.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 53.11 16.06 0.71 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.441 -0.787 . . . . 0.0 110.861 -168.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 115.94 3.27 19.97 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.888 171.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.528 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 25.4 t -99.41 111.48 23.84 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.364 -1.668 . . . . 0.0 109.24 174.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.454 ' SG ' ' O ' ' A' ' 3' ' ' THR . 26.1 p -78.29 125.69 29.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.92 -1.112 . . . . 0.0 111.248 -170.484 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.528 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -135.52 170.55 15.78 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.306 -0.871 . . . . 0.0 109.3 169.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.445 HG22 ' N ' ' B' ' 51' ' ' VAL . 39.0 m -102.49 151.37 22.39 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.836 -1.165 . . . . 0.0 110.727 -174.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' B' ' 59' ' ' VAL . 17.9 t -78.05 112.52 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.574 -0.704 . . . . 0.0 110.169 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.54 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 42.1 p -69.49 -40.07 77.26 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.186 -0.946 . . . . 0.0 109.821 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.503 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -165.45 151.82 9.9 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.833 -178.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.536 HD13 ' CG2' ' B' ' 38' ' ' THR . 8.1 mt -106.44 131.67 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 0.0 110.012 174.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.455 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.2 m-80 -105.59 65.51 0.71 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.529 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -115.47 4.37 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -172.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.553 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.23 -21.07 43.25 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.294 . . . . 0.0 109.233 175.9 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.596 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 8.4 m170 -75.26 158.74 32.43 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 110.096 -177.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.639 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 86.0 t -141.58 120.32 9.94 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.968 174.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.52 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 22.4 m -87.25 128.56 35.16 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.682 -0.636 . . . . 0.0 109.781 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.639 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 97.7 m-85 -113.58 159.98 19.03 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.908 -1.12 . . . . 0.0 110.044 177.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.8 p-10 -93.73 147.28 23.19 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.023 -1.048 . . . . 0.0 111.375 -177.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.59 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -154.89 115.25 3.86 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.496 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 52.0 ttm -70.77 139.41 51.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.757 -1.215 . . . . 0.0 109.372 178.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.47 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 20.0 tttt -59.98 -42.64 94.64 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.078 -1.014 . . . . 0.0 110.143 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -69.67 -40.06 76.63 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.496 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 93.9 m -61.04 -35.49 77.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.014 -1.054 . . . . 0.0 109.276 172.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.59 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 26.8 tp -60.01 -42.94 95.41 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.23 -0.919 . . . . 0.0 109.237 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 49.9 ttt85 -69.98 -40.04 75.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 110.656 173.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.502 ' CG2' HG21 ' B' ' 71' ' ' THR . 1.0 OUTLIER -63.06 -41.76 94.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.125 -177.171 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.502 HG21 ' CG2' ' B' ' 70' ' ' ILE . 16.3 p -88.79 -174.36 4.48 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.064 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 1.9 t30 -102.95 24.25 11.01 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 171.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.537 ' CD1' HD22 ' B' ' 63' ' ' LEU . 72.5 mt -67.98 -40.0 83.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.968 -1.083 . . . . 0.0 110.116 175.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.529 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -45.31 -23.9 0.85 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.0 p-10 -65.69 -19.6 65.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.014 -1.286 . . . . 0.0 110.681 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.3 mt -61.15 143.74 54.93 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.12 -0.987 . . . . 0.0 110.849 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.486 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 74.6 mttt -147.67 139.47 24.04 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.671 -0.643 . . . . 0.0 109.744 175.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.579 ' CG2' ' CG1' ' B' ' 15' ' ' ILE . 20.0 t -61.93 154.04 5.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 120.803 -1.186 . . . . 0.0 110.429 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.51 -14.34 59.95 Favored Glycine 0 N--CA 1.482 1.708 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 -174.088 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.455 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 32.7 t0 -99.94 169.9 8.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.41 -1.053 . . . . 0.0 109.595 176.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.594 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.8 m95 -117.42 168.18 10.6 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.956 -1.09 . . . . 0.0 110.269 177.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.544 ' CG1' ' CB ' ' B' ' 10' ' ' ALA . 1.5 p -129.86 154.76 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.465 -0.772 . . . . 0.0 109.997 -178.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.474 ' HB2' ' HB3' ' A' ' 72' ' ' ASN . 2.2 m-20 -80.39 107.31 13.08 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.107 -0.996 . . . . 0.0 109.32 168.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.446 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -107.65 139.36 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.435 -1.416 . . . . 0.0 111.085 -175.588 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -136.49 141.51 43.48 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.049 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.455 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 50.1 ptt85 -81.9 131.96 35.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.171 -0.955 . . . . 0.0 110.975 -175.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.624 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -126.17 145.89 50.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 176.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -133.22 143.18 48.98 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.577 -0.702 . . . . 0.0 110.403 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 14.6 mmtp -70.05 -39.98 75.36 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 110.16 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 55.0 p90 -147.94 159.98 43.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 110.048 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.483 ' O ' HG12 ' B' ' 94' ' ' ILE . 37.4 t -149.94 160.61 43.46 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.199 -0.938 . . . . 0.0 110.529 -177.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -66.73 -40.02 88.2 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.346 -0.846 . . . . 0.0 110.482 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.579 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 9.2 tt0 -99.67 47.87 0.95 Allowed 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.673 1.225 . . . . 0.0 109.428 -174.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' B' ' 96' ' ' GLY . 19.4 mm -69.52 -40.01 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.701 -1.249 . . . . 0.0 110.416 173.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . -36.39 92.0 0.01 OUTLIER Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -173.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . -71.29 156.06 52.81 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 74.0 t60 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.314 -1.11 . . . . 10.460000000000001 110.229 179.959 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.541 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.54 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.0 mtt . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.232 0.539 . . . . 0.0 110.332 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.963 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 5.3 p90 -169.76 139.61 2.0 Allowed 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.211 -0.93 . . . . 0.0 108.898 173.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.546 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 65.4 p -133.92 -38.04 0.89 Allowed 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.145 -0.972 . . . . 0.0 109.404 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.512 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 53.16 19.31 7.57 Favored Glycine 0 N--CA 1.482 1.727 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -177.019 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 1.006 HD11 HC81 ' B' ' 99' ' ' RBF . 81.2 mt -78.97 128.62 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.098 -1.236 . . . . 0.0 109.734 -176.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.827 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -93.39 136.61 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.056 -1.027 . . . . 0.0 110.816 -171.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -71.82 -30.9 65.99 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.609 -0.682 . . . . 0.0 111.391 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.61 178.96 31.92 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.401 -1.857 . . . . 0.0 110.52 -172.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.462 ' HA ' HG22 ' A' ' 84' ' ' VAL . 24.0 p -127.92 169.99 13.34 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.163 -1.198 . . . . 0.0 110.624 -179.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.087 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -137.39 149.05 46.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.509 -0.745 . . . . 0.0 109.545 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.2 tttt -103.72 115.62 30.82 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 120.937 -1.102 . . . . 0.0 110.121 178.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.026 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.6 tp -59.71 127.27 31.16 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 120.885 -1.134 . . . . 0.0 108.526 171.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.091 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.6 p -129.37 -31.76 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.591 -0.843 . . . . 0.0 110.129 -176.598 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.42 141.8 28.74 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.044 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.797 HG23 ' CD2' ' A' ' 24' ' ' HIS . 9.5 mt -109.03 134.88 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.104 -0.998 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.4 m-20 -109.55 115.16 29.4 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.404 -0.81 . . . . 0.0 109.824 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.43 113.88 27.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.109 -0.994 . . . . 0.0 110.635 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.0 mtmt -113.88 126.03 28.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.204 -0.935 . . . . 0.0 108.952 174.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.39 -22.88 12.8 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.751 1.395 . . . . 0.0 110.128 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.577 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 13.1 m-80 -79.91 -41.86 25.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.96 174.853 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.577 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.0 m-85 -156.61 150.32 24.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.454 -0.779 . . . . 0.0 110.022 -178.597 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.513 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.2 ttt180 -91.26 144.84 25.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.781 -1.199 . . . . 0.0 110.236 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.513 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.7 m -129.82 138.1 50.82 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.611 -0.681 . . . . 0.0 109.668 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.797 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.91 140.05 51.85 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.903 -1.123 . . . . 0.0 111.24 178.747 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.757 HG22 ' OG ' ' A' ' 60' ' ' SER . 10.8 t -119.99 134.12 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.061 -1.024 . . . . 0.0 110.542 -176.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 11.3 m -119.26 170.03 9.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 CA-C-O 121.082 0.468 . . . . 0.0 110.14 -178.028 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.586 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 11.3 tt0 -103.53 117.68 34.98 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.393 -0.817 . . . . 0.0 108.951 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 33' ' ' LEU . 10.2 tp -83.49 130.24 56.96 Favored Pre-proline 0 C--N 1.298 -1.641 0 O-C-N 121.405 -0.809 . . . . 0.0 110.144 -173.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 29.0 Cg_endo -67.69 175.89 5.7 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 O-C-N 123.935 1.492 . . . . 0.0 111.041 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 54.1 t0 -59.97 -40.02 87.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.292 -0.88 . . . . 0.0 111.161 -174.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.605 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.73 56.95 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.77 -1.206 . . . . 0.0 110.803 -174.084 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.605 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.53 -15.65 13.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.903 -1.123 . . . . 0.0 109.713 170.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.603 HD21 ' HB2' ' A' ' 57' ' ' ASN . 27.2 mt -68.39 -34.35 75.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.327 -0.858 . . . . 0.0 110.182 175.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 50.7 t0 -89.6 111.75 22.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 110.288 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 120.29 -53.92 0.67 Allowed Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.323 176.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.651 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.5 tt -60.07 147.97 37.4 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.906 -1.349 . . . . 0.0 110.792 -174.48 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.651 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.9 pt-20 -143.43 166.91 23.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.478 -0.764 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.661 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.69 154.69 41.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 179.577 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.82 0.36 59.45 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -175.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.507 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.45 160.11 26.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -1.169 . . . . 0.0 109.406 176.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.477 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -98.37 112.18 24.27 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.883 -1.136 . . . . 0.0 109.816 177.227 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.664 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -102.05 127.84 55.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.377 -0.827 . . . . 0.0 109.164 175.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.92 119.84 32.63 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.228 173.13 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.733 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.2 m80 -90.05 107.66 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.75 -0.78 . . . . 0.0 108.905 177.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 53.02 16.07 0.68 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.436 -0.79 . . . . 0.0 110.92 -168.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.501 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 116.08 2.96 19.99 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.911 171.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.683 ' HB2' HD22 ' B' ' 45' ' ' ASN . 24.7 t -99.22 111.53 23.89 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.356 -1.673 . . . . 0.0 109.269 174.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.465 ' C ' HD23 ' A' ' 49' ' ' LEU . 26.1 p -78.35 125.6 29.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.983 -1.073 . . . . 0.0 111.269 -170.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.998 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -135.34 170.52 15.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.245 -0.909 . . . . 0.0 109.363 169.939 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -102.54 151.23 22.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.757 -1.214 . . . . 0.0 110.786 -175.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.935 HG22 ' CE2' ' A' ' 61' ' ' PHE . 17.8 t -77.88 112.57 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.73 -0.606 . . . . 0.0 110.118 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.545 HG22 ' HB3' ' A' ' 62' ' ' ASP . 42.1 p -69.59 -40.0 76.96 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.25 -0.906 . . . . 0.0 109.822 176.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.616 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.5 tt0 -165.44 151.82 9.92 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.816 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.661 HD11 ' N ' ' A' ' 38' ' ' THR . 8.1 mt -106.45 131.68 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.197 -0.939 . . . . 0.0 110.021 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.501 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.7 m-80 -105.55 65.52 0.72 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.544 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.62 -115.37 4.37 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -172.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.603 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.28 -20.88 43.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.015 -1.285 . . . . 0.0 109.226 175.874 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.091 ' CE1' HG11 ' A' ' 13' ' ' VAL . 15.7 m-70 -75.48 158.94 31.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.176 -0.952 . . . . 0.0 109.998 -177.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.732 ' CG1' HG13 ' A' ' 51' ' ' VAL . 86.0 t -141.65 120.27 9.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 C-N-CA 119.11 -1.036 . . . . 0.0 111.007 174.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.757 ' OG ' HG22 ' A' ' 25' ' ' VAL . 22.0 m -87.17 128.36 35.13 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.711 -0.618 . . . . 0.0 109.819 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.998 ' HB3' HD12 ' A' ' 49' ' ' LEU . 97.8 m-85 -113.44 159.97 18.94 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.854 -1.154 . . . . 0.0 110.03 177.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.545 ' HB3' HG22 ' A' ' 52' ' ' THR . 32.9 p-10 -93.68 147.27 23.18 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.126 -0.984 . . . . 0.0 111.456 -178.045 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.754 HD22 HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -154.93 115.22 3.84 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -176.665 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.53 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 52.2 ttm -70.75 139.42 51.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.254 . . . . 0.0 109.388 178.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.493 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 20.0 tttt -60.08 -42.56 94.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.019 -1.05 . . . . 0.0 110.129 -177.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -69.72 -39.96 76.54 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.881 -1.137 . . . . 0.0 109.986 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.606 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 94.1 m -61.14 -35.38 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.891 -1.131 . . . . 0.0 109.242 172.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.754 HD13 HD22 ' A' ' 63' ' ' LEU . 26.7 tp -60.01 -43.24 95.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.107 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 49.9 ttt85 -69.83 -39.98 76.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.263 -0.898 . . . . 0.0 110.678 173.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.903 HG22 HG23 ' A' ' 71' ' ' THR . 1.0 OUTLIER -63.03 -41.78 94.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.163 -0.961 . . . . 0.0 109.185 -177.171 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.903 HG23 HG22 ' A' ' 70' ' ' ILE . 16.2 p -88.85 -174.47 4.51 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.071 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 1.8 t30 -102.98 24.31 10.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 171.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.694 ' HB3' HD21 ' A' ' 63' ' ' LEU . 71.7 mt -68.03 -39.96 83.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.051 . . . . 0.0 110.099 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.55 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -45.3 -23.92 0.86 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -65.71 -19.54 65.94 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.049 -1.265 . . . . 0.0 110.686 -176.409 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.3 mt -61.19 143.74 54.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.2 -0.937 . . . . 0.0 110.831 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.026 ' C ' HD23 ' A' ' 12' ' ' LEU . 74.6 mttt -147.68 139.57 24.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.644 -0.66 . . . . 0.0 109.761 175.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.745 HG21 HG13 ' A' ' 15' ' ' ILE . 20.0 t -61.97 154.05 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 120.789 -1.194 . . . . 0.0 110.412 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.69 -14.67 59.42 Favored Glycine 0 N--CA 1.481 1.683 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -174.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 33.2 t0 -99.86 170.0 8.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.416 -1.05 . . . . 0.0 109.54 176.329 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.9 m95 -117.4 168.24 10.54 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.943 -1.098 . . . . 0.0 110.327 176.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.087 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -129.88 154.7 40.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.442 -0.786 . . . . 0.0 110.004 -178.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.827 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -80.47 107.53 13.35 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.107 -0.996 . . . . 0.0 109.164 168.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.55 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -107.82 139.19 30.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.412 -1.43 . . . . 0.0 111.163 -175.762 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -136.34 141.47 43.76 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.09 -178.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.481 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 50.1 ptt85 -81.92 131.85 35.26 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.175 -0.953 . . . . 0.0 111.046 -175.425 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.932 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -126.14 145.81 50.21 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.271 -0.893 . . . . 0.0 110.19 176.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -133.09 143.12 49.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.674 -0.642 . . . . 0.0 110.54 -177.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.6 mmtp -69.95 -40.02 75.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.259 -0.901 . . . . 0.0 110.196 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -148.02 159.99 43.32 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.31 -0.869 . . . . 0.0 110.074 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.471 ' HB3' HG12 ' A' ' 94' ' ' ILE . 37.4 t -149.96 160.61 43.47 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.179 -0.951 . . . . 0.0 110.509 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -66.51 -36.75 83.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 110.569 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -143.25 72.22 1.36 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.032 -1.043 . . . . 0.0 110.463 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.471 HG12 ' HB3' ' A' ' 91' ' ' SER . 25.0 mm -59.99 -45.04 95.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.309 -0.87 . . . . 0.0 109.686 174.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 83.31 -45.94 3.55 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 91.22 119.97 2.35 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -177.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.271 -1.134 . . . . 10.119999999999999 110.202 -179.314 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.3 mtt . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 120.968 0.413 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.932 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 5.2 p90 -167.23 139.48 3.34 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.955 -1.091 . . . . 0.0 109.06 171.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.531 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 65.0 p -133.97 -38.05 0.89 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.089 -1.007 . . . . 0.0 109.364 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 53.15 19.39 7.66 Favored Glycine 0 N--CA 1.482 1.738 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.021 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 1.018 HD11 HC81 ' A' ' 98' ' ' RBF . 81.1 mt -79.05 128.59 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 109.745 -176.521 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.864 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -93.33 136.68 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.05 -1.032 . . . . 0.0 110.795 -171.262 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -71.98 -30.48 65.3 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.641 -0.662 . . . . 0.0 111.448 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.95 178.69 32.36 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 118.515 -1.802 . . . . 0.0 110.603 -172.177 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.448 ' HA ' HG22 ' B' ' 84' ' ' VAL . 23.9 p -127.9 169.94 13.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.156 -1.202 . . . . 0.0 110.657 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.1 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -137.35 149.18 46.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.563 -0.711 . . . . 0.0 109.497 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.591 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.2 tttt -103.75 115.73 31.02 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.004 -1.06 . . . . 0.0 110.057 178.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.03 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.6 tp -59.93 127.27 31.06 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.964 -1.085 . . . . 0.0 108.579 171.788 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.095 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.6 p -129.24 -32.03 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.143 -176.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.26 141.74 28.88 Favored 'General case' 0 C--N 1.296 -1.725 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.121 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.789 HG23 ' CD2' ' B' ' 24' ' ' HIS . 9.7 mt -108.94 134.88 49.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.119 -0.988 . . . . 0.0 110.29 173.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.517 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.66 115.31 29.65 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.464 -0.772 . . . . 0.0 109.8 173.139 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.48 113.87 27.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.066 -1.021 . . . . 0.0 110.569 -175.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.0 mtmt -113.9 125.9 28.79 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.9 . . . . 0.0 109.07 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.4 Cg_endo -51.35 -22.91 12.69 Favored 'Trans proline' 0 C--N 1.304 -1.795 0 O-C-N 123.708 1.373 . . . . 0.0 110.105 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 13.1 m-80 -79.78 -42.26 24.85 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 109.867 174.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.0 m-85 -156.33 150.33 25.17 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 110.001 -178.516 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.51 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.2 ttt180 -91.2 144.74 25.31 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.872 -1.142 . . . . 0.0 110.319 179.2 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.517 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 98.5 m -129.78 138.12 50.88 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.603 -0.686 . . . . 0.0 109.73 -177.103 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.789 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.8 140.12 51.86 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.941 -1.099 . . . . 0.0 111.156 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.757 HG22 ' OG ' ' B' ' 60' ' ' SER . 10.7 t -119.98 134.21 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 110.568 -176.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 11.3 m -119.43 170.04 9.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.904 -0.498 . . . . 0.0 110.046 -177.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.594 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 11.3 tt0 -103.51 117.75 35.15 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.394 -0.816 . . . . 0.0 108.976 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.49 HD23 ' HA ' ' B' ' 33' ' ' LEU . 10.2 tp -83.45 130.11 57.6 Favored Pre-proline 0 C--N 1.298 -1.646 0 O-C-N 121.234 -0.917 . . . . 0.0 110.195 -173.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.49 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 29.0 Cg_endo -67.67 175.91 5.67 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 O-C-N 123.895 1.471 . . . . 0.0 111.041 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.426 ' HA ' HD12 ' B' ' 33' ' ' LEU . 54.0 t0 -60.01 -40.02 87.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.29 -0.881 . . . . 0.0 111.126 -174.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.97 0.61 57.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.785 -1.197 . . . . 0.0 110.74 -174.039 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.44 -15.67 13.86 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.851 -1.156 . . . . 0.0 109.724 170.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.609 HD21 ' HB2' ' B' ' 57' ' ' ASN . 27.1 mt -68.38 -34.35 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.33 -0.856 . . . . 0.0 110.178 175.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -89.64 111.73 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -0.92 . . . . 0.0 110.278 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 120.39 -53.95 0.67 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.782 -1.199 . . . . 0.0 110.363 176.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.653 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.5 tt -59.99 148.04 36.84 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.975 -1.309 . . . . 0.0 110.817 -174.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.653 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.9 pt-20 -143.46 166.92 23.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.656 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.72 154.68 41.64 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.057 -1.027 . . . . 0.0 110.081 179.567 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.8 0.35 59.3 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -175.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.499 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -79.54 160.02 26.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -1.181 . . . . 0.0 109.408 176.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.481 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -98.15 111.98 24.11 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.821 -1.175 . . . . 0.0 109.957 177.239 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.674 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.6 t -102.06 127.86 55.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.398 -0.814 . . . . 0.0 109.13 175.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.86 119.78 32.53 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.277 173.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.734 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.2 m80 -89.98 107.63 19.23 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.354 -0.841 . . . . 0.0 109.009 177.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.683 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 53.11 16.06 0.71 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.441 -0.787 . . . . 0.0 110.861 -168.36 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.512 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 115.94 3.27 19.97 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.888 171.294 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.647 ' O ' HD23 ' B' ' 49' ' ' LEU . 25.4 t -99.41 111.48 23.84 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.364 -1.668 . . . . 0.0 109.24 174.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.458 ' C ' HD23 ' B' ' 49' ' ' LEU . 26.1 p -78.29 125.69 29.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.92 -1.112 . . . . 0.0 111.248 -170.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.996 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -135.52 170.55 15.78 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.306 -0.871 . . . . 0.0 109.3 169.93 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 39.0 m -102.49 151.37 22.39 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.836 -1.165 . . . . 0.0 110.727 -174.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.93 HG22 ' CE2' ' B' ' 61' ' ' PHE . 17.9 t -78.05 112.52 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.574 -0.704 . . . . 0.0 110.169 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.561 HG22 ' HB3' ' B' ' 62' ' ' ASP . 42.1 p -69.49 -40.07 77.26 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.186 -0.946 . . . . 0.0 109.821 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.614 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.4 tt0 -165.45 151.82 9.9 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.833 -178.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.656 HD11 ' N ' ' B' ' 38' ' ' THR . 8.1 mt -106.44 131.67 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 0.0 110.012 174.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.49 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.2 m-80 -105.59 65.51 0.71 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.529 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -115.47 4.37 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -172.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.609 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.23 -21.07 43.25 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.294 . . . . 0.0 109.233 175.9 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.095 ' CE1' HG11 ' B' ' 13' ' ' VAL . 16.1 m-70 -75.26 158.74 32.43 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 110.096 -177.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.732 ' CG1' HG13 ' B' ' 51' ' ' VAL . 86.0 t -141.58 120.32 9.94 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.968 174.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.757 ' OG ' HG22 ' B' ' 25' ' ' VAL . 22.4 m -87.25 128.56 35.16 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.682 -0.636 . . . . 0.0 109.781 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.996 ' HB3' HD12 ' B' ' 49' ' ' LEU . 97.7 m-85 -113.58 159.98 19.03 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.908 -1.12 . . . . 0.0 110.044 177.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.561 ' HB3' HG22 ' B' ' 52' ' ' THR . 32.8 p-10 -93.73 147.28 23.19 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.023 -1.048 . . . . 0.0 111.375 -177.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.753 HD22 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -154.89 115.25 3.86 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.751 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.515 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 52.0 ttm -70.77 139.41 51.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.757 -1.215 . . . . 0.0 109.372 178.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.489 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 20.0 tttt -59.98 -42.64 94.64 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.078 -1.014 . . . . 0.0 110.143 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -69.67 -40.06 76.63 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.608 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 93.9 m -61.04 -35.49 77.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.014 -1.054 . . . . 0.0 109.276 172.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.753 HD13 HD22 ' B' ' 63' ' ' LEU . 26.8 tp -60.01 -42.94 95.41 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.23 -0.919 . . . . 0.0 109.237 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 49.9 ttt85 -69.98 -40.04 75.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 110.656 173.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.853 HG22 HG23 ' B' ' 71' ' ' THR . 1.0 OUTLIER -63.06 -41.76 94.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.125 -177.171 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.853 HG23 HG22 ' B' ' 70' ' ' ILE . 16.3 p -88.79 -174.36 4.48 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.064 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 1.9 t30 -102.95 24.25 11.01 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 171.229 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.694 ' HB3' HD21 ' B' ' 63' ' ' LEU . 72.5 mt -67.98 -40.0 83.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.968 -1.083 . . . . 0.0 110.116 175.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.546 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -45.31 -23.9 0.85 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.0 p-10 -65.69 -19.6 65.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.014 -1.286 . . . . 0.0 110.681 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.3 mt -61.15 143.74 54.93 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.12 -0.987 . . . . 0.0 110.849 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.03 ' C ' HD23 ' B' ' 12' ' ' LEU . 74.6 mttt -147.67 139.47 24.04 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.671 -0.643 . . . . 0.0 109.744 175.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' B' ' 15' ' ' ILE . 20.0 t -61.93 154.04 5.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 120.803 -1.186 . . . . 0.0 110.429 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.51 -14.34 59.95 Favored Glycine 0 N--CA 1.482 1.708 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 -174.088 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.455 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 32.7 t0 -99.94 169.9 8.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.41 -1.053 . . . . 0.0 109.595 176.138 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.591 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.8 m95 -117.42 168.18 10.6 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.956 -1.09 . . . . 0.0 110.269 177.06 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.1 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -129.86 154.76 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.465 -0.772 . . . . 0.0 109.997 -178.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.864 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.2 m-20 -80.39 107.31 13.08 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.107 -0.996 . . . . 0.0 109.32 168.262 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.542 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -107.65 139.36 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.435 -1.416 . . . . 0.0 111.085 -175.588 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -136.49 141.51 43.48 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.049 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.471 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 50.1 ptt85 -81.9 131.96 35.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.171 -0.955 . . . . 0.0 110.975 -175.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.963 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -126.17 145.89 50.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 176.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -133.22 143.18 48.98 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.577 -0.702 . . . . 0.0 110.403 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 14.6 mmtp -70.05 -39.98 75.36 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 110.16 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 55.0 p90 -147.94 159.98 43.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 110.048 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.511 ' O ' HG12 ' B' ' 94' ' ' ILE . 37.4 t -149.94 160.61 43.46 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.199 -0.938 . . . . 0.0 110.529 -177.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -66.73 -40.02 88.2 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.346 -0.846 . . . . 0.0 110.482 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.579 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 9.2 tt0 -99.67 47.87 0.95 Allowed 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.673 1.225 . . . . 0.0 109.428 -174.207 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' B' ' 96' ' ' GLY . 19.4 mm -69.52 -40.01 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.701 -1.249 . . . . 0.0 110.416 173.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . -36.39 92.0 0.01 OUTLIER Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -173.438 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . -71.29 156.06 52.81 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 74.0 t60 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.314 -1.11 . . . . 10.140000000000001 110.229 179.959 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 1.018 HC81 HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 1.006 HC81 HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 66.0 mtt . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.232 0.539 . . . . 0.0 110.332 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.963 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 5.3 p90 -169.76 139.61 2.0 Allowed 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.211 -0.93 . . . . 0.0 108.898 173.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.546 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 65.4 p -133.92 -38.04 0.89 Allowed 'General case' 0 C--N 1.296 -1.751 0 O-C-N 121.145 -0.972 . . . . 0.0 109.404 -177.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.512 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 53.16 19.31 7.57 Favored Glycine 0 N--CA 1.482 1.727 0 N-CA-C 109.033 -1.627 . . . . 0.0 109.033 -177.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 1.006 HD11 HC81 ' B' ' 99' ' ' RBF . 81.2 mt -78.97 128.62 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.098 -1.236 . . . . 0.0 109.734 -176.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.827 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -93.39 136.61 24.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.056 -1.027 . . . . 0.0 110.816 -171.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -71.82 -30.9 65.99 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.609 -0.682 . . . . 0.0 111.391 177.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.61 178.96 31.92 Favored Glycine 0 N--CA 1.494 2.504 0 C-N-CA 118.401 -1.857 . . . . 0.0 110.52 -172.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.462 ' HA ' HG22 ' A' ' 84' ' ' VAL . 24.0 p -127.92 169.99 13.34 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.163 -1.198 . . . . 0.0 110.624 -179.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.087 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -137.39 149.05 46.66 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.509 -0.745 . . . . 0.0 109.545 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.2 tttt -103.72 115.62 30.82 Favored 'General case' 0 C--N 1.294 -1.81 0 O-C-N 120.937 -1.102 . . . . 0.0 110.121 178.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.026 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.6 tp -59.71 127.27 31.16 Favored 'General case' 0 C--N 1.297 -1.695 0 O-C-N 120.885 -1.134 . . . . 0.0 108.526 171.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.109 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.37 -31.76 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.591 -0.843 . . . . 0.0 110.129 -176.598 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.42 141.8 28.74 Favored 'General case' 0 N--CA 1.492 1.646 0 C-N-CA 119.09 -1.044 . . . . 0.0 111.044 -179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.797 HG23 ' CD2' ' A' ' 24' ' ' HIS . 9.5 mt -109.03 134.88 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.104 -0.998 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.4 m-20 -109.55 115.16 29.4 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.404 -0.81 . . . . 0.0 109.824 173.167 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.43 113.88 27.74 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.109 -0.994 . . . . 0.0 110.635 -175.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.0 mtmt -113.88 126.03 28.63 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.204 -0.935 . . . . 0.0 108.952 174.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.39 -22.88 12.8 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.751 1.395 . . . . 0.0 110.128 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.577 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 13.1 m-80 -79.91 -41.86 25.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.247 -0.908 . . . . 0.0 109.96 174.853 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.577 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.0 m-85 -156.61 150.32 24.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.454 -0.779 . . . . 0.0 110.022 -178.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.513 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.2 ttt180 -91.26 144.84 25.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.781 -1.199 . . . . 0.0 110.236 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.513 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.7 m -129.82 138.1 50.82 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.611 -0.681 . . . . 0.0 109.668 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.797 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.91 140.05 51.85 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.903 -1.123 . . . . 0.0 111.24 178.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.757 HG22 ' OG ' ' A' ' 60' ' ' SER . 10.8 t -119.99 134.12 64.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.061 -1.024 . . . . 0.0 110.542 -176.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 11.3 m -119.26 170.03 9.34 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 CA-C-O 121.082 0.468 . . . . 0.0 110.14 -178.028 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 11.3 tt0 -103.53 117.68 34.98 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.393 -0.817 . . . . 0.0 108.951 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 33' ' ' LEU . 10.2 tp -83.49 130.24 56.96 Favored Pre-proline 0 C--N 1.298 -1.641 0 O-C-N 121.405 -0.809 . . . . 0.0 110.144 -173.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 29.0 Cg_endo -67.69 175.89 5.7 Favored 'Trans proline' 0 C--N 1.308 -1.557 0 O-C-N 123.935 1.492 . . . . 0.0 111.041 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 54.1 t0 -59.97 -40.02 87.67 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.292 -0.88 . . . . 0.0 111.161 -174.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.605 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.73 56.95 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.77 -1.206 . . . . 0.0 110.803 -174.084 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.605 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.53 -15.65 13.84 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.903 -1.123 . . . . 0.0 109.713 170.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.603 HD21 ' HB2' ' A' ' 57' ' ' ASN . 27.2 mt -68.39 -34.35 75.88 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.327 -0.858 . . . . 0.0 110.182 175.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 50.7 t0 -89.6 111.75 22.77 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.316 -0.865 . . . . 0.0 110.288 -179.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 120.29 -53.92 0.67 Allowed Glycine 0 N--CA 1.493 2.451 0 C-N-CA 119.795 -1.193 . . . . 0.0 110.323 176.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.651 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.5 tt -60.07 147.97 37.4 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.906 -1.349 . . . . 0.0 110.792 -174.48 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.651 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.9 pt-20 -143.43 166.91 23.47 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.478 -0.764 . . . . 0.0 109.718 -179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.661 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.69 154.69 41.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.076 -1.015 . . . . 0.0 110.096 179.577 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.82 0.36 59.45 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -175.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.507 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.45 160.11 26.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.213 -1.169 . . . . 0.0 109.406 176.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.477 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -98.37 112.18 24.27 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.883 -1.136 . . . . 0.0 109.816 177.227 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.664 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -102.05 127.84 55.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.377 -0.827 . . . . 0.0 109.164 175.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.92 119.84 32.63 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.228 173.13 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.733 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.2 m80 -90.05 107.66 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.75 -0.78 . . . . 0.0 108.905 177.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 53.02 16.07 0.68 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.436 -0.79 . . . . 0.0 110.92 -168.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.501 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 116.08 2.96 19.99 Favored Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.911 171.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.646 ' O ' HD23 ' A' ' 49' ' ' LEU . 24.7 t -99.22 111.53 23.89 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.356 -1.673 . . . . 0.0 109.269 174.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.465 ' C ' HD23 ' A' ' 49' ' ' LEU . 26.1 p -78.35 125.6 29.58 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.983 -1.073 . . . . 0.0 111.269 -170.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.998 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -135.34 170.52 15.8 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.245 -0.909 . . . . 0.0 109.363 169.939 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -102.54 151.23 22.57 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.757 -1.214 . . . . 0.0 110.786 -175.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.935 HG22 ' CE2' ' A' ' 61' ' ' PHE . 17.8 t -77.88 112.57 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.73 -0.606 . . . . 0.0 110.118 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.545 HG22 ' HB3' ' A' ' 62' ' ' ASP . 42.1 p -69.59 -40.0 76.96 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.25 -0.906 . . . . 0.0 109.822 176.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.616 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.5 tt0 -165.44 151.82 9.92 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 119.385 -0.926 . . . . 0.0 110.816 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.661 HD11 ' N ' ' A' ' 38' ' ' THR . 8.1 mt -106.45 131.68 55.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.197 -0.939 . . . . 0.0 110.021 174.277 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.501 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.7 m-80 -105.55 65.52 0.72 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 120.119 -0.632 . . . . 0.0 109.544 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.62 -115.37 4.37 Favored Glycine 0 N--CA 1.486 2.014 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -172.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.603 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.28 -20.88 43.41 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.015 -1.285 . . . . 0.0 109.226 175.874 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.109 ' CD2' HG11 ' A' ' 13' ' ' VAL . 8.2 m170 -75.48 158.94 31.89 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.176 -0.952 . . . . 0.0 109.998 -177.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.732 ' CG1' HG13 ' A' ' 51' ' ' VAL . 86.0 t -141.65 120.27 9.69 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 C-N-CA 119.11 -1.036 . . . . 0.0 111.007 174.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.757 ' OG ' HG22 ' A' ' 25' ' ' VAL . 22.0 m -87.17 128.36 35.13 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.711 -0.618 . . . . 0.0 109.819 178.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.998 ' HB3' HD12 ' A' ' 49' ' ' LEU . 97.8 m-85 -113.44 159.97 18.94 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.854 -1.154 . . . . 0.0 110.03 177.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.545 ' HB3' HG22 ' A' ' 52' ' ' THR . 32.9 p-10 -93.68 147.27 23.18 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.126 -0.984 . . . . 0.0 111.456 -178.045 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.754 HD22 HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -154.93 115.22 3.84 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -176.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.53 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 52.2 ttm -70.75 139.42 51.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.693 -1.254 . . . . 0.0 109.388 178.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.493 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 20.0 tttt -60.08 -42.56 94.87 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.019 -1.05 . . . . 0.0 110.129 -177.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -69.72 -39.96 76.54 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 120.881 -1.137 . . . . 0.0 109.986 178.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.606 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 94.1 m -61.14 -35.38 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.891 -1.131 . . . . 0.0 109.242 172.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.754 HD13 HD22 ' A' ' 63' ' ' LEU . 26.7 tp -60.01 -43.24 95.35 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.138 -0.976 . . . . 0.0 109.107 179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 49.9 ttt85 -69.83 -39.98 76.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.263 -0.898 . . . . 0.0 110.678 173.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.903 HG22 HG23 ' A' ' 71' ' ' THR . 1.0 OUTLIER -63.03 -41.78 94.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.163 -0.961 . . . . 0.0 109.185 -177.171 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.903 HG23 HG22 ' A' ' 70' ' ' ILE . 16.2 p -88.85 -174.47 4.51 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 175.071 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 1.8 t30 -102.98 24.31 10.95 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 171.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.694 ' HB3' HD21 ' A' ' 63' ' ' LEU . 71.7 mt -68.03 -39.96 83.01 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.019 -1.051 . . . . 0.0 110.099 175.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.55 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -45.3 -23.92 0.86 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.318 -1.113 . . . . 0.0 110.318 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -65.71 -19.54 65.94 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.049 -1.265 . . . . 0.0 110.686 -176.409 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.3 mt -61.19 143.74 54.99 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.2 -0.937 . . . . 0.0 110.831 -176.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.026 ' C ' HD23 ' A' ' 12' ' ' LEU . 74.6 mttt -147.68 139.57 24.11 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.644 -0.66 . . . . 0.0 109.761 175.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.745 HG21 HG13 ' A' ' 15' ' ' ILE . 20.0 t -61.97 154.05 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 120.789 -1.194 . . . . 0.0 110.412 -175.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.69 -14.67 59.42 Favored Glycine 0 N--CA 1.481 1.683 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -174.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 33.2 t0 -99.86 170.0 8.84 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.416 -1.05 . . . . 0.0 109.54 176.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.9 m95 -117.4 168.24 10.54 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.943 -1.098 . . . . 0.0 110.327 176.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.087 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -129.88 154.7 40.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.442 -0.786 . . . . 0.0 110.004 -178.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.827 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -80.47 107.53 13.35 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.107 -0.996 . . . . 0.0 109.164 168.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.55 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -107.82 139.19 30.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.412 -1.43 . . . . 0.0 111.163 -175.762 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -136.34 141.47 43.76 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.09 -178.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.481 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 50.1 ptt85 -81.92 131.85 35.26 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.175 -0.953 . . . . 0.0 111.046 -175.425 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.932 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -126.14 145.81 50.21 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.271 -0.893 . . . . 0.0 110.19 176.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -133.09 143.12 49.11 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.674 -0.642 . . . . 0.0 110.54 -177.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 14.6 mmtp -69.95 -40.02 75.69 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.259 -0.901 . . . . 0.0 110.196 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -148.02 159.99 43.32 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.31 -0.869 . . . . 0.0 110.074 179.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.471 ' HB3' HG12 ' A' ' 94' ' ' ILE . 37.4 t -149.96 160.61 43.47 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.179 -0.951 . . . . 0.0 110.509 -177.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -66.51 -36.75 83.49 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.322 -0.861 . . . . 0.0 110.569 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -143.25 72.22 1.36 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.032 -1.043 . . . . 0.0 110.463 -176.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.471 HG12 ' HB3' ' A' ' 91' ' ' SER . 25.0 mm -59.99 -45.04 95.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.309 -0.87 . . . . 0.0 109.686 174.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 83.31 -45.94 3.55 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 177.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.566 ' O ' ' CD2' ' A' ' 97' ' ' HIS . . . 91.22 119.97 2.35 Favored Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -177.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.566 ' CD2' ' O ' ' A' ' 96' ' ' GLY . 20.3 m170 . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.271 -1.134 . . . . 10.119999999999999 110.202 -179.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.3 mtt . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 120.968 0.413 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.932 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 5.2 p90 -167.23 139.48 3.34 Favored 'General case' 0 C--N 1.306 -1.306 0 O-C-N 120.955 -1.091 . . . . 0.0 109.06 171.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.531 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 65.0 p -133.97 -38.05 0.89 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.089 -1.007 . . . . 0.0 109.364 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 53.15 19.39 7.66 Favored Glycine 0 N--CA 1.482 1.738 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.021 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 1.018 HD11 HC81 ' A' ' 98' ' ' RBF . 81.1 mt -79.05 128.59 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 109.745 -176.521 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.864 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -93.33 136.68 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.05 -1.032 . . . . 0.0 110.795 -171.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -71.98 -30.48 65.3 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.641 -0.662 . . . . 0.0 111.448 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.95 178.69 32.36 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 118.515 -1.802 . . . . 0.0 110.603 -172.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.448 ' HA ' HG22 ' B' ' 84' ' ' VAL . 23.9 p -127.9 169.94 13.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.156 -1.202 . . . . 0.0 110.657 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.1 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -137.35 149.18 46.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.563 -0.711 . . . . 0.0 109.497 -177.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.591 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.2 tttt -103.75 115.73 31.02 Favored 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.004 -1.06 . . . . 0.0 110.057 178.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.03 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.6 tp -59.93 127.27 31.06 Favored 'General case' 0 C--N 1.298 -1.651 0 O-C-N 120.964 -1.085 . . . . 0.0 108.579 171.788 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.108 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.24 -32.03 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.143 -176.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -145.26 141.74 28.88 Favored 'General case' 0 C--N 1.296 -1.725 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.121 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.789 HG23 ' CD2' ' B' ' 24' ' ' HIS . 9.7 mt -108.94 134.88 49.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.119 -0.988 . . . . 0.0 110.29 173.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.517 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.66 115.31 29.65 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.464 -0.772 . . . . 0.0 109.8 173.139 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.48 113.87 27.72 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.066 -1.021 . . . . 0.0 110.569 -175.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.0 mtmt -113.9 125.9 28.79 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.9 . . . . 0.0 109.07 174.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.407 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.4 Cg_endo -51.35 -22.91 12.69 Favored 'Trans proline' 0 C--N 1.304 -1.795 0 O-C-N 123.708 1.373 . . . . 0.0 110.105 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 13.1 m-80 -79.78 -42.26 24.85 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.301 -0.875 . . . . 0.0 109.867 174.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.0 m-85 -156.33 150.33 25.17 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 110.001 -178.516 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.51 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.2 ttt180 -91.2 144.74 25.31 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.872 -1.142 . . . . 0.0 110.319 179.2 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.517 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 98.5 m -129.78 138.12 50.88 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.603 -0.686 . . . . 0.0 109.73 -177.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.789 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.8 140.12 51.86 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 120.941 -1.099 . . . . 0.0 111.156 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.757 HG22 ' OG ' ' B' ' 60' ' ' SER . 10.7 t -119.98 134.21 64.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.234 -0.916 . . . . 0.0 110.568 -176.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.503 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 11.3 m -119.43 170.04 9.55 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 121.904 -0.498 . . . . 0.0 110.046 -177.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 11.3 tt0 -103.51 117.75 35.15 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.394 -0.816 . . . . 0.0 108.976 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.49 HD23 ' HA ' ' B' ' 33' ' ' LEU . 10.2 tp -83.45 130.11 57.6 Favored Pre-proline 0 C--N 1.298 -1.646 0 O-C-N 121.234 -0.917 . . . . 0.0 110.195 -173.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.49 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 29.0 Cg_endo -67.67 175.91 5.67 Favored 'Trans proline' 0 C--N 1.309 -1.537 0 O-C-N 123.895 1.471 . . . . 0.0 111.041 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.426 ' HA ' HD12 ' B' ' 33' ' ' LEU . 54.0 t0 -60.01 -40.02 87.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.29 -0.881 . . . . 0.0 111.126 -174.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.97 0.61 57.0 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.785 -1.197 . . . . 0.0 110.74 -174.039 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.44 -15.67 13.86 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.851 -1.156 . . . . 0.0 109.724 170.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.609 HD21 ' HB2' ' B' ' 57' ' ' ASN . 27.1 mt -68.38 -34.35 75.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.33 -0.856 . . . . 0.0 110.178 175.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 50.6 t0 -89.64 111.73 22.77 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.228 -0.92 . . . . 0.0 110.278 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 120.39 -53.95 0.67 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.782 -1.199 . . . . 0.0 110.363 176.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.653 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.5 tt -59.99 148.04 36.84 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.975 -1.309 . . . . 0.0 110.817 -174.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.653 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.9 pt-20 -143.46 166.92 23.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.436 -0.79 . . . . 0.0 109.737 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.656 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.72 154.68 41.64 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.057 -1.027 . . . . 0.0 110.081 179.567 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.8 0.35 59.3 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -175.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.499 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -79.54 160.02 26.65 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -1.181 . . . . 0.0 109.408 176.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.481 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -98.15 111.98 24.11 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 120.821 -1.175 . . . . 0.0 109.957 177.239 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.674 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.6 t -102.06 127.86 55.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.398 -0.814 . . . . 0.0 109.13 175.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.86 119.78 32.53 Favored 'General case' 0 C--N 1.298 -1.672 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.277 173.08 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.734 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.2 m80 -89.98 107.63 19.23 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.354 -0.841 . . . . 0.0 109.009 177.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 53.11 16.06 0.71 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.441 -0.787 . . . . 0.0 110.861 -168.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.512 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 115.94 3.27 19.97 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.888 171.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.647 ' O ' HD23 ' B' ' 49' ' ' LEU . 25.4 t -99.41 111.48 23.84 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.364 -1.668 . . . . 0.0 109.24 174.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.458 ' C ' HD23 ' B' ' 49' ' ' LEU . 26.1 p -78.29 125.69 29.71 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.92 -1.112 . . . . 0.0 111.248 -170.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.996 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -135.52 170.55 15.78 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.306 -0.871 . . . . 0.0 109.3 169.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 39.0 m -102.49 151.37 22.39 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.836 -1.165 . . . . 0.0 110.727 -174.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.93 HG22 ' CE2' ' B' ' 61' ' ' PHE . 17.9 t -78.05 112.52 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.574 -0.704 . . . . 0.0 110.169 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.561 HG22 ' HB3' ' B' ' 62' ' ' ASP . 42.1 p -69.49 -40.07 77.26 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.186 -0.946 . . . . 0.0 109.821 176.774 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.614 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.4 tt0 -165.45 151.82 9.9 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.833 -178.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.656 HD11 ' N ' ' B' ' 38' ' ' THR . 8.1 mt -106.44 131.67 55.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.306 -0.871 . . . . 0.0 110.012 174.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.49 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.2 m-80 -105.59 65.51 0.71 Allowed 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.529 178.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -115.47 4.37 Favored Glycine 0 N--CA 1.487 2.043 0 N-CA-C 108.605 -1.798 . . . . 0.0 108.605 -172.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.609 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.23 -21.07 43.25 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.001 -1.294 . . . . 0.0 109.233 175.9 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.108 ' CD2' HG11 ' B' ' 13' ' ' VAL . 8.4 m170 -75.26 158.74 32.43 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 110.096 -177.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.732 ' CG1' HG13 ' B' ' 51' ' ' VAL . 86.0 t -141.58 120.32 9.94 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.968 174.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.757 ' OG ' HG22 ' B' ' 25' ' ' VAL . 22.4 m -87.25 128.56 35.16 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.682 -0.636 . . . . 0.0 109.781 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.996 ' HB3' HD12 ' B' ' 49' ' ' LEU . 97.7 m-85 -113.58 159.98 19.03 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.908 -1.12 . . . . 0.0 110.044 177.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.561 ' HB3' HG22 ' B' ' 52' ' ' THR . 32.8 p-10 -93.73 147.28 23.19 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.023 -1.048 . . . . 0.0 111.375 -177.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.753 HD22 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -154.89 115.25 3.86 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -176.751 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.515 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 52.0 ttm -70.77 139.41 51.02 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.757 -1.215 . . . . 0.0 109.372 178.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.489 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 20.0 tttt -59.98 -42.64 94.64 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.078 -1.014 . . . . 0.0 110.143 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -69.67 -40.06 76.63 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.914 -1.116 . . . . 0.0 109.965 178.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.608 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 93.9 m -61.04 -35.49 77.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.014 -1.054 . . . . 0.0 109.276 172.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.753 HD13 HD22 ' B' ' 63' ' ' LEU . 26.8 tp -60.01 -42.94 95.41 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.23 -0.919 . . . . 0.0 109.237 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 49.9 ttt85 -69.98 -40.04 75.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.206 -0.934 . . . . 0.0 110.656 173.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.853 HG22 HG23 ' B' ' 71' ' ' THR . 1.0 OUTLIER -63.06 -41.76 94.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.239 -0.913 . . . . 0.0 109.125 -177.171 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.853 HG23 HG22 ' B' ' 70' ' ' ILE . 16.3 p -88.79 -174.36 4.48 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 175.064 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 1.9 t30 -102.95 24.25 11.01 Favored 'General case' 0 C--N 1.294 -1.808 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 171.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.694 ' HB3' HD21 ' B' ' 63' ' ' LEU . 72.5 mt -67.98 -40.0 83.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.968 -1.083 . . . . 0.0 110.116 175.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.546 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -45.31 -23.9 0.85 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 -179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.0 p-10 -65.69 -19.6 65.96 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.014 -1.286 . . . . 0.0 110.681 -176.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.3 mt -61.15 143.74 54.93 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.12 -0.987 . . . . 0.0 110.849 -176.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.03 ' C ' HD23 ' B' ' 12' ' ' LEU . 74.6 mttt -147.67 139.47 24.04 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.671 -0.643 . . . . 0.0 109.744 175.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' B' ' 15' ' ' ILE . 20.0 t -61.93 154.04 5.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 120.803 -1.186 . . . . 0.0 110.429 -175.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.51 -14.34 59.95 Favored Glycine 0 N--CA 1.482 1.708 0 N-CA-C 108.593 -1.803 . . . . 0.0 108.593 -174.088 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.455 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 32.7 t0 -99.94 169.9 8.89 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.41 -1.053 . . . . 0.0 109.595 176.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.591 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.8 m95 -117.42 168.18 10.6 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.956 -1.09 . . . . 0.0 110.269 177.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.1 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -129.86 154.76 40.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.465 -0.772 . . . . 0.0 109.997 -178.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.864 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.2 m-20 -80.39 107.31 13.08 Favored 'General case' 0 C--N 1.296 -1.747 0 O-C-N 121.107 -0.996 . . . . 0.0 109.32 168.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.542 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -107.65 139.36 29.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 120.435 -1.416 . . . . 0.0 111.085 -175.588 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -136.49 141.51 43.48 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.049 -178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.471 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 50.1 ptt85 -81.9 131.96 35.26 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.171 -0.955 . . . . 0.0 110.975 -175.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.963 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -126.17 145.89 50.19 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 176.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -133.22 143.18 48.98 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.577 -0.702 . . . . 0.0 110.403 -177.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 14.6 mmtp -70.05 -39.98 75.36 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 110.16 179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 55.0 p90 -147.94 159.98 43.29 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.332 -0.855 . . . . 0.0 110.048 179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.511 ' O ' HG12 ' B' ' 94' ' ' ILE . 37.4 t -149.94 160.61 43.46 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.199 -0.938 . . . . 0.0 110.529 -177.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 75.7 m-20 -66.73 -40.02 88.2 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.346 -0.846 . . . . 0.0 110.482 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.579 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 9.2 tt0 -99.67 47.87 0.95 Allowed 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 122.673 1.225 . . . . 0.0 109.428 -174.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.528 ' O ' ' N ' ' B' ' 96' ' ' GLY . 19.4 mm -69.52 -40.01 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.701 -1.249 . . . . 0.0 110.416 173.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.45 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . -36.39 92.0 0.01 OUTLIER Glycine 0 N--CA 1.496 2.636 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -173.438 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . -71.29 156.06 52.81 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 74.0 t60 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.314 -1.11 . . . . 10.140000000000001 110.229 179.959 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 1.018 HC81 HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 1.006 HC81 HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_